Anthem Biosciences (ANTHEM) Share Price Fall Streak Extends to Second Straight Session
- October 14, 2026
- Posted by: Kunal Singla
- Category: News
Anthem Biosciences Share Price Fall Streak is now in its second straight session, with the stock trading at Rs 849.8, down 2.36% from the previous close and lower by Rs 20.55. Univest data confirms the move itself, though no company-specific trigger has been identified. The cumulative move across the streak stands at -3.77% from the starting level of Rs 883.1. Anthem Biosciences Share Price Fall Streak therefore reflects a two-session decline rather than a one-off gap in trade, and the latest traded price matters because it keeps the pattern intact at 14 October 2026 at 2:23:03 PM IST.
Anthem Biosciences Share Price Fall Streak is being watched in the context of a Rs 49,765.16 crore market capitalisation and a large-cap profile. For readers, a second straight session matters more than a single-day dip because it shows the decline has persisted across consecutive trading days. The latest move also keeps Anthem Biosciences Share Price Fall Streak within a price range that still needs to be read against valuation, sector benchmarks and peer multiples rather than against the day’s open alone. Univest data shows the stock is still in active price discovery during the session.
Anthem Biosciences (ANTHEM) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 849.8 |
| Previous Close | Rs 870.35 |
| Today's Move | -Rs 20.55 (-2.36%) |
| Open | Rs 870 |
| High | Rs 870 |
| Low | Rs 849.8 |
| Market Capitalisation | Rs 49,765.16 crore |
Anthem Biosciences Share Price Fall Streak opened at Rs 870, matched the day’s high at Rs 870, and later touched a low of Rs 849.8, which is also the latest traded price as of 14 October 2026 at 2:23:03 PM IST. The stock is trading below the previous close of Rs 870.35 by Rs 20.55, or 2.36%. That places the latest print at the lower end of the day’s range after the session began near the prior settlement level. Anthem Biosciences Share Price Fall Streak also comes with a market capitalisation of Rs 49,765.16 crore, keeping it in the large-cap category for context. The move is notable because the decline has held through the session rather than reversing back toward the open. For Univest readers, this is the clearest intraday read on Anthem Biosciences Share Price Fall Streak before looking at valuation.
What the Consecutive Declines Show
Anthem Biosciences Share Price Fall Streak has now extended over two consecutive trading sessions, which means the market is not looking at an isolated weaker print. The cumulative fall of 3.77% from Rs 883.1 to Rs 849.8 is the main data point that separates this article from a one-session update. That streak measure matters because it captures the combined effect of both down sessions in one number. Anthem Biosciences Share Price Fall Streak is therefore better read as a short run of lower pricing rather than a single intraday move. According to Univest data, the pattern is confirmed, but the figures alone do not establish a company-specific reason. For tracking purposes, the key question is whether the next traded price stabilises above or below the current band.
Anthem Biosciences (ANTHEM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 49,765.16 crore |
| P/E Ratio | 85.16x |
| P/B Ratio | 15.67x |
| ROE | 21.98% |
| ROCE | 29.62% |
| EPS | Rs 10.22 |
| Book Value Per Share | Rs 55.53 |
| Dividend Yield | 0.23% |
Anthem Biosciences (ANTHEM) fundamental metrics show P/E 85.16x, P/B 15.67x, ROE 21.98%, ROCE 29.62%. Read together, these ratios describe the company’s position rather than a recommendation.
Anthem Biosciences has a market capitalisation of Rs 49,765.16 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 85.16x, P/B at 15.67x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 21.98% and ROCE of 29.62%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 10.22, book value per share of Rs 55.53, dividend yield of 0.23%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.72x, median ROE of 11.61%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 85.16x |
| Benchmark Median P/E | 31.72x |
| Benchmark Average P/E | 46.74x |
| Benchmark P/E Range | 3.11x to 663.29x |
| Company P/B Ratio | 15.67x |
| Benchmark Median P/B | 2.91x |
| Benchmark Average P/B | 4.27x |
| Company ROE | 21.98% |
| Benchmark Median ROE | 11.61% |
| Benchmark Average ROE | 10.59% |
| Company ROCE | 29.62% |
| Benchmark Median ROCE | 13.46% |
| Benchmark Average ROCE | 13.35% |
| Company Market Capitalisation | Rs 49,765.16 crore |
| Benchmark Median Market Cap | Rs 821.94 crore |
| Benchmark Average Market Cap | Rs 13,782.64 crore |
Anthem Biosciences (ANTHEM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Anthem Biosciences (ANTHEM) has a P/E ratio of 85.16x, which is above the benchmark median of 31.72x, a difference of +168.47%. The P/E comparison frames valuation; it is not a signal to buy or sell.
Anthem Biosciences (ANTHEM) has a ROE of 21.98%, which is above the benchmark median of 11.61%, a difference of +89.32%. Anthem Biosciences (ANTHEM) has a ROCE of 29.62%, which is above the benchmark median of 13.46%, a difference of +120.06%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,22,067.01 | 35.09 | 4.91 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,48,982.98 | 84.18 | 13.94 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,77,974.12 | 80.83 | 19.64 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,13,615.69 | 25 | 4.18 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,11,898.66 | 101.36 | 19.65 | 18.31 | 18.2 |
Anthem Biosciences (ANTHEM) has a P/E ratio of 85.16x compared with the displayed peer median of 80.83x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 21.98% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 29.62% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Anthem Biosciences (ANTHEM) has a market capitalisation of Rs 49,765.16 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Anthem Biosciences
- Anthem Biosciences Share Price Fall Streak is in its second straight session, so the decline is being tracked as a pattern rather than an isolated move.
- The latest traded price of Rs 849.8 is below the previous close of Rs 870.35, keeping Anthem Biosciences Share Price Fall Streak in focus for intraday price action.
- The cumulative fall of 3.77% from Rs 883.1 gives the streak its wider context.
- Valuation remains premium, with a P/E of 85.16 and P/B of 15.67 alongside ROE of 21.98% and ROCE of 29.62%.
- The stock still sits in the large-cap category, which helps readers compare Anthem Biosciences Share Price Fall Streak with the broader healthcare universe.
About Anthem Biosciences
Anthem Biosciences Share Price Fall Streak belongs to a company in the Healthcare sector and the Pharmaceuticals & Drugs industry. The business context matters because the stock is being assessed against a pharma peer set, not a generic market list. Anthem Biosciences Share Price Fall Streak is best understood as a market read on a large-cap healthcare name with high return ratios and premium multiples. That makes the share price movement more relevant to valuation watchers on Univest than to traders looking only at day-to-day swings.
Track Anthem Biosciences Share Price on Univest
Use Anthem Biosciences (ANTHEM) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Anthem Biosciences Share Price Fall Streak can be tracked on Univest alongside live price updates, valuation ratios, 52-week levels and market insights. Readers can use the platform to follow Anthem Biosciences Share Price Fall Streak together with its P/E, P/B, ROE, ROCE, EPS and book value in one place. The same view also helps compare the stock with healthcare peers and the broader industry benchmark without losing the price context.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Anthem Biosciences Share Price Fall Streak in focus today?
Ans. Anthem Biosciences Share Price Fall Streak is in focus because the stock is lower for a second straight session and is trading at Rs 849.8, down 2.36% from the previous close. The cumulative decline is 3.77% from Rs 883.1.
What is the latest traded price in Anthem Biosciences Share Price Fall Streak?
Ans. The latest traded price is Rs 849.8 as of 14 October 2026 at 2:23:03 PM IST. Anthem Biosciences Share Price Fall Streak also shows a day low of Rs 849.8 and a day high of Rs 870.
How much has Anthem Biosciences Share Price Fall Streak moved over two sessions?
Ans. Anthem Biosciences Share Price Fall Streak has fallen 3.77% cumulatively from the streak start base of Rs 883.1. That makes the move a two-session decline, not a one-day fluctuation, and the latest price remains below the previous close.
What does the intraday range show in Anthem Biosciences Share Price Fall Streak?
Ans. Anthem Biosciences Share Price Fall Streak opened at Rs 870, touched a high of Rs 870 and a low of Rs 849.8. The latest traded price sat at the day’s low, which keeps the session’s weakness visible in the.
What are the key valuation metrics in Anthem Biosciences Share Price Fall Streak?
Ans. Anthem Biosciences Share Price Fall Streak sits on a P/E of 85.16 and a P/B of 15.67. EPS is Rs 10.22, book value is Rs 55.53 and dividend yield is 0.23%, all of which frame the premium valuation.
How do ROE and ROCE look in Anthem Biosciences Share Price Fall Streak?
Ans. Anthem Biosciences Share Price Fall Streak shows ROE of 21.98% and ROCE of 29.62%. Both figures are above the same-industry benchmark median and average, which keeps the stock’s return ratios strong despite the decline.
How does Anthem Biosciences Share Price Fall Streak compare with the healthcare benchmark?
Ans. Anthem Biosciences Share Price Fall Streak remains above the healthcare benchmark on valuation, with P/E and P/B both higher than the same-industry median and average. Its ROE and ROCE are also above the benchmark levels.
How does Anthem Biosciences Share Price Fall Streak compare with peers?
Ans. Anthem Biosciences Share Price Fall Streak has a P/E close to Divi’s Laboratories and above Sun Pharmaceutical and Zydus Lifesciences in the peer set shown. Its ROE and ROCE are also stronger than several listed peers.
What should readers monitor next for Anthem Biosciences Share Price Fall Streak?
Ans. Readers should monitor the next traded price, whether the stock holds above the current range, and how the streak compares with its premium valuation. Univest also helps track market capitalisation, EPS, book value and peer multiples in one view.
